Application submitted to the European Medicines Agency (EMA) for use of Pradaxa < sup > ® < /sup > in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE
Application submitted to the European Medicines Agency (EMA) for use of Pradaxa < sup > ® < /sup > in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: European Medicines Agency (EMA) | Pradaxa | Pulmonary Thromboembolism | Research | Thrombosis